NanoString Technologies, Inc. Description
NanoString Technologies, Inc. engages in the development, manufacture, and sale instruments and consumables for use in life sciences research applications. The company provides nCounter Analysis System, an automated, multi-application, digital detection, and counting system that includes nCounter Prep Station, an automated liquid handling component for processing and preparing the samples for data collection; and nCounter Digital Analyzer, which collects data from samples through the images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files. Its nCounter Analysis System supports research and the development of future clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, a data analysis program that offers nCounter Analysis System users the ability to quality check, normalize, and analyze their data. In addition, it provides gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits, and human karyotype panels; custom CodeSets; and master kits that are ancillary reagents, cartridges, tips, and reagent plates to setup and process samples in its instruments. Further, the company plans to develop and sell diagnostic kits for use in molecular diagnostic testing in clinical laboratories. It markets its systems and related consumables to researchers in academic, government, and biopharmaceutical laboratories for use in understanding fundamental biology and the molecular basis of disease in North America, Europe, the Middle East, and the Asia Pacific. The company was founded in 2003 and is headquartered in Seattle, Washington.